Barely Significant
← all excerpts

An open-label study evaluating the safety and efficacy of AMO-01 for the treatment of seizures in Phelan-McDermid syndrome.

HGG Adv · 2025 · PMC11772936 · PMID 39690738

Europe PMCDOI
1
hedged sentence
0.0400
closest p · 0.8× alpha
0.0400
boldest claim

The sentences

nominally significantp = 0.04actually significant
The ABC showed a nominally significant reduction in the hyperactivity subscale, but only at week 2 ( p = 0.04) and lethargy at week 4 ( p = 0.04), although large effect sizes were again seen in the majority of the ABC subscales at some time points ( Table 4 ).

also in 2,106 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.